Home Institutions MD Anderson Cancer Center clinical trials Institution Directory
Clinical trials at MD Anderson Cancer Center Sites in Houston, TX
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:26 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2388
Current sort
Recently updated
Campus scope
MD Anderson Cancer Center, Houston, TX
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 61–72 of 2,388 matching trials with a site at MD Anderson Cancer Center, Houston, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Peripheral T Cell Lymphoma
Interventions Belinostat Injection, Pralatrexate Injection, CHOP, COP Drug
Lead sponsor Acrotech Biopharma Inc. Industry
Eligibility 18 Years and older
Enrollment 504 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2030
U.S. locations 10
States / cities Clovis, California • Santa Monica, California • Aurora, Colorado + 7 more
Conditions Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Interventions Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging Drug · Procedure · Biological
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older
Enrollment 86 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 55
States / cities Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 48 more
Conditions Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography Procedure · Drug
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older
Enrollment 30 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2027
U.S. locations 27
States / cities Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more
Conditions Advanced or Metastatic Solid Tumors
Interventions TAK-188 Drug
Lead sponsor Takeda Industry
Eligibility 18 Years and older
Enrollment 273 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2029
U.S. locations 15
States / cities Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more
Conditions Endometrial Cancer
Interventions Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation Radiation · Other
Lead sponsor Canadian Cancer Trials Group Network
Eligibility 18 Years and older · Female only
Enrollment 393 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2029
U.S. locations 77
States / cities Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 61 more
Conditions Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography Procedure · Radiation · Drug
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older · Male only
Enrollment 35 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2027
U.S. locations 13
States / cities Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Conditions Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging Drug · Procedure
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older
Enrollment 42 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2027
U.S. locations 4
States / cities Boston, Massachusetts • Galveston, Texas • Houston, Texas
Conditions Localized Skin Lesion, Mycosis Fungoides
Interventions Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy Other · Radiation
Lead sponsor M.D. Anderson Cancer Center Other
Eligibility 18 Years and older
Enrollment 49 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2018 – 2027
U.S. locations 1
States / cities Houston, Texas
Conditions Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions ABBV-400, Itraconazole (ITZ), Bevacizumab Drug
Lead sponsor AbbVie Industry
Eligibility 18 Years and older
Enrollment 325 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2027
U.S. locations 20
States / cities Duarte, California • San Francisco, California • Aurora, Colorado + 15 more
Conditions Secondary Immune Deficiency
Interventions IgPro20 Biological
Lead sponsor CSL Behring Industry
Eligibility 18 Years and older
Enrollment 63 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 17
States / cities Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
Conditions Breast Cancer
Interventions LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 18 Years and older
Enrollment 260 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2026
U.S. locations 17
States / cities Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 12 more
Conditions Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Interventions Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human Procedure · Biological
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older
Enrollment 600 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2032
U.S. locations 286
States / cities Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 228 more About this MD Anderson Cancer Center institution page
What this page lists ClinicalTrials.gov records that list MD Anderson Cancer Center in Houston, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , trials led by M.D. Anderson Cancer Center at any site , browse by condition , or browse by U.S. city .